SCHEMBL14282914

SCHEMBL14282914

Nc1cc(-c2ccnc(Cl)c2)[nH]c1N1CCC(O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.39
CDC7 O00311 2/20 0.39
ROCK2 O75116 2/20 0.39
MAPKAPK2 P49137 2/20 0.39
GSK3B P49841 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
MAP4K4 O95819 1/20 0.39
HIPK2 Q9H2X6 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
KCNMA1 Q12791 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
CDK1 P06493 3/20 0.36
STK3 Q13188 2/20 0.36
STK4 Q13043 1/20 0.36
LRRK2 Q5S007 1/20 0.36
MAPK12 P53778 2/20 0.35
MAPK13 O15264 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14283718 0.87 KCNMA1 (0.41) CDK2CDC7ROCK2MAPKAPK2GSK3B
SCHEMBL14283679 0.86 CDC7 (0.42) CDK2CDC7ROCK2MAPKAPK2GSK3B
SCHEMBL14283164 0.83 ATR (0.44) CDK2CDC7ROCK2MAPKAPK2GSK3B
SCHEMBL3617304 0.83 KCNMA1 (0.44) CDK2CDC7ROCK2MAPKAPK2GSK3B
SCHEMBL14283758 0.80 CDC7 (0.40) CDK2CDC7ROCK2MAPKAPK2GSK3B
SCHEMBL14282909 0.79 CKS1B (0.45) MAP4K4ITGB2ICAM1ITGALJAK2
SCHEMBL14283184 0.76 BTK (0.43) MAP4K4ITGB2ICAM1ITGALAURKA
SCHEMBL14283324 0.76 KIT (0.49) MAP4K4JAK2SMARCA2SMARCA4PBRM1
SCHEMBL14283157 0.73 KIT (0.47) MAP4K4SMARCA2SMARCA4PBRM1KIT
SCHEMBL3610126 0.71 CDC7 (0.46) CDK2CDC7ROCK2MAPKAPK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 WO disclosed